Puma Biotechnology achieved its third consecutive year of profitability in 2025. For Q4 2025, the company reported total revenue of $75.5 million, a significant increase from $59.1 million in Q4 2024, primarily due to higher product and royalty revenues. While GAAP net income decreased year-over-year due to tax valuation allowance adjustments, the company maintained a strong cash position and significantly reduced its total debt.

Puma Biotechnology reported a net income of $8.8 million for Q3 2025, a significant decrease from $20.3 million in Q3 2024. Total revenue also declined to $54.5 million from $80.5 million in the prior year, primarily due to reduced international product supply revenue and lower royalty revenue, partially offset by increased U.S. NERLYNX® sales.

Puma Biotechnology delivered a robust performance in Q2 2025, with total revenue reaching $52.4 million, up from $47.1 million in Q2 2024. The company achieved a net income of $5.9 million, a substantial turnaround from a net loss of $4.5 million in the same period last year. This positive shift was primarily fueled by increased product revenue from NERLYNX® and reduced selling, general, and administrative expenses.

Puma Biotechnology reported a net income of $3.0 million for the first quarter of 2025, a significant improvement compared to a net loss in the same period last year. Total revenue increased to $46.0 million, driven by higher net product revenue from NERLYNX.

Puma Biotechnology announced strong financial results for the fourth quarter of 2024, with net income increasing to $19.3 million and product revenue reaching $54.4 million. The company also reported positive net income for the third consecutive year, driven by commercial performance and strategic initiatives.

Puma Biotechnology reported a net income of $20.3 million and total revenue of $80.5 million for the third quarter of 2024. The company is also progressing with the clinical development of alisertib.

Puma Biotechnology reported a decrease in total revenue to $47.1 million and a net loss of $4.5 million for the second quarter of 2024. The decline in revenue was primarily driven by lower product revenue from NERLYNX. The company is focusing on the development of alisertib and anticipates key milestones in the next 12 months.

Puma Biotechnology reported a net loss of $4.8 million for Q1 2024, compared to a net income of $1.4 million in Q1 2023. Product revenue decreased to $40.3 million from $46.8 million year-over-year. The company initiated a Phase II clinical trial of alisertib monotherapy for extensive stage small cell lung cancer.

Puma Biotechnology reported a net income of $12.3 million for the fourth quarter of 2023, compared to a net loss of $5.6 million for the same period in 2022. Total revenue for the quarter was $72.2 million, with product revenue contributing $53.2 million and royalty revenue $19.0 million.

Puma Biotechnology announced its Q3 2023 financial results, with a net income of $5.8 million, or $0.12 per basic and diluted share, compared to a net loss of $0.4 million in Q3 2022. Total revenue was $56.1 million, including $51.6 million from product revenue and $4.5 million from royalty revenue.

Puma Biotechnology reported a net product revenue increase for Q2 2023 compared to Q2 2022. The company also achieved positive net income and cash flow during the quarter. They anticipate key milestones over the next 12 months, including initiating a Phase II clinical trial of alisertib in small cell lung cancer.

Puma Biotechnology reported a net income of $1.4 million for Q1 2023, a significant improvement from the net loss of $3.4 million in Q1 2022. Total revenue increased to $52.8 million, driven by growth in both net product revenue and royalty revenue.

Puma Biotechnology reported its Q4 and full year financial results, with Q4 product revenue reaching $53.7 million. The company reported a net loss of $5.6 million for the quarter, influenced by an increase in legal accrual. Key milestones were achieved, including presentations of updated findings from clinical trials.

Puma Biotechnology reported a net loss of $0.4 million, or $0.01 per share, for the third quarter of 2022. Total revenue for the third quarter of 2022 was $57.1 million, which includes $54.3 million from NERLYNX net product revenue.

Puma Biotechnology reported positive net income and earnings per share for the second quarter of 2022, driven by worldwide commercial revenues and royalties from NERLYNX, coupled with ongoing efforts to reduce operating expenses.

Puma Biotechnology reported a net loss of $3.4 million for the first quarter of 2022, compared to a net income of $16.5 million in the first quarter of 2021. Product revenue, net was $40.7 million, down from $45.8 million in the prior year. Total revenue was $45.7 million, which includes royalty revenue of $5.0 million.

Puma Biotechnology reported financial results for the fourth quarter and year ended December 31, 2021. The company's total revenue for Q4 2021 was $55.4 million, with a net income of $4.2 million, or $0.10 per basic and diluted share. Non-GAAP adjusted net income was $8.4 million, or $0.21 per basic and diluted share.

Puma Biotechnology reported a net loss of $44.7 million for Q3 2021, compared to a net loss of $31.5 million for Q3 2020. Total revenue for Q3 2021 was $46.2 million, a decrease from $50.8 million in Q3 2020. The results were negatively impacted by COVID-19 and inventory reduction.

Puma Biotechnology reported a slight increase in net NERLYNX revenue to $48.9 million in Q2 2021 from $48.8 million in Q2 2020. The company reported a net loss of $5.1 million, or $0.13 per share, compared to a net income of $3.4 million, or $0.09 per share, for the same period in the previous year. Non-GAAP adjusted net income was $13.1 million, or $0.32 per share, compared to $14.0 million, or $0.36 per share, for the second quarter of 2020. Cash, cash equivalents and marketable securities totaled $108.9 million as of June 30, 2021.

Puma Biotechnology reported a net income of $16.5 million, or $0.40 per diluted share, for the first quarter of 2021, compared to a net loss of $16.9 million, or $0.43 per share, for the first quarter of 2020. Total revenue increased to $98.2 million, driven by $50.0 million in license revenue and $45.8 million in net product revenue. The company had cash, cash equivalents and marketable securities of $109.1 million at the end of the quarter.

Puma Biotechnology reported a net loss of $15.0 million for the fourth quarter of 2020, with NERLYNX revenue at $50.0 million. The company continued to be impacted by COVID-19 challenges but met revenue guidance. Positive clinical milestones were achieved, and key milestones are anticipated over the next 12 months.

Puma Biotechnology reported a net loss of $31.5 million for Q3 2020, impacted by COVID-19 challenges. Total revenue was $50.8 million, with NERLYNX revenue at $49.3 million. The company continued to advance clinical milestones and support breast cancer patients.

Puma Biotechnology reported a net income of $3.4 million for the second quarter of 2020, a significant improvement compared to the net loss of $37.4 million in the same quarter of the previous year. NERLYNX product revenue was $48.8 million, slightly lower than the $53.8 million in Q2 2019. Total revenue for the quarter was $70.6 million, including license and royalty revenue.

Puma Biotechnology reported a net loss of $16.9 million, or $0.43 per share, for the first quarter of 2020. Net product revenue was $48.6 million, compared to $45.6 million in the first quarter of 2019. Total revenue for the first quarter of 2020 was $51.2 million, compared to $99.1 million for the first quarter of 2019.

Puma Biotechnology reported a net loss of $11.2 million for the fourth quarter of 2019, compared to a net loss of $30.7 million for the fourth quarter of 2018. Net product revenue in the fourth quarter of 2019 was $58.7 million, compared to $61.1 million in the fourth quarter of 2018. Non-GAAP adjusted net income was $0.3 million, compared to a non-GAAP adjusted net loss of $12.2 million for the fourth quarter of 2018.